Gyre Therapeutics, Inc. stock is up 208.08% since 30 days ago. The next earnings date is Dec 21, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 17 November’s closed higher than October.
Catalyst Biosciences, Inc. focuses on developing protease product candidates in the fields of hemostasis and complement regulation. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD) and CB 4332 for patients with deficiencies in complement factor I (CFI)